Could a drug combo free liver transplant patients from daily anti-rejection pills?

NCT ID NCT06832189

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether switching from the standard anti-rejection drug tacrolimus to everolimus plus epoetin can safely allow liver transplant recipients to stop all immunosuppressants. Twenty stable adult patients who received a liver transplant 1–10 years ago will take part. The main goal is to see if this approach is safe and can lead to 'operational tolerance'—where the body accepts the new liver without needing lifelong medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwestern University Feinberg School of Medicine

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco School of Medicine

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania Medical Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••